(Q37394708)

20 August 2017

Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML. (English)

1 reference

20 August 2017

1 reference

K M Bernot

1

1 reference

20 August 2017

R F Siebenaler

2

1 reference

20 August 2017

S P Whitman

3

1 reference

20 August 2017

N A Zorko

4

1 reference

20 August 2017

G G Marcucci

5

1 reference

20 August 2017

R Santhanam

6

1 reference

20 August 2017

E H Ahmed

7

1 reference

20 August 2017

M Ngangana

8

1 reference

20 August 2017

K K McConnell

9

1 reference

20 August 2017

J S Nemer

10

1 reference

20 August 2017

D L Brook

11

1 reference

20 August 2017

S K Kulp

12

1 reference

20 August 2017

C S Chen

13

1 reference

20 August 2017

D Frankhouser

14

1 reference

20 August 2017

P Yan

15

1 reference

20 August 2017

R Bundschuh

16

1 reference

20 August 2017

X Zhang

17

1 reference

20 August 2017

A M Dorrance

18

1 reference

20 August 2017

K E Dickerson

19

1 reference

20 August 2017

D Jarjoura

20

1 reference

20 August 2017

W Blum

21

1 reference

20 August 2017

G Marcucci

22

1 reference

20 August 2017

M A Caligiuri

23

1 reference

20 August 2017

10 May 2013

1 reference

20 August 2017

1 reference

20 August 2017

27

1 reference

20 August 2017

12

1 reference

20 August 2017

2379-2382

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2013.147

20 August 2017

0 references

cites work

Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864138

Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864138

Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864138

The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864138

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864138

DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864138

Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864138

Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864138

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864138

Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864138

The partial tandem duplication of ALL1 (MLL) is consistently generated by Alu-mediated homologous recombination in acute myeloid leukemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864138

Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864138

Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3864138

Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML

2 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23660685

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23660685

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/LEU.2013.147

1 reference

Dimensions Publication ID

20 August 2017

0 references

1 reference

20 August 2017

PubMed publication ID

23660685

1 reference